MiNK Therapeutics, Inc.
INKT evidence brief
What we can confirm
- BioSniper Score:
- 3.7 / 10
- Market Cap:
- $61.2M
- Lead Asset:
- agent-797 (Phase 2)
What it means
What to watch
Prepared research question
What matters most for INKT—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INKT
MiNK Therapeutics, Inc. (INKT) is a publicly traded biotechnology company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with its lead candidate agenT-797 in Phase 2 clinical trials.
Key risk: Limited cash runway
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate · 2 clinical trials for MiNK Therapeutics, Inc..
MiNK Therapeutics, Inc. (INKT) is a publicly traded biotechnology company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with its lead candidate agenT-797 in Phase 2 clinical trials.
- Lead candidate agenT-797 is a native allogeneic iNKT cell therapy being evaluated in a randomized Phase 2 trial for severe acute lung injury and ARDS, with preliminary data expected in the second half of 2026 [news · 2026-05-15].
- The company reported cash & equivalents of $8.8M and a net loss of -$3.1M for the period ending 2026-06-30 [sec].
- MiNK has an accumulated deficit of $162.5 million as of 2026-08-13 [sec_mda · as of 2026-08-13].
- An investigator-sponsored Phase 1 trial of agenT-797 for GVHD prevention is supported by non-dilutive NIH STTR and Mary Gooze Clinical Trial Award funding, with first patient dosing expected in mid-2026 [sec_mda · as of 2026-08-13].
- The company’s pipeline includes next-generation engineered iNKT programs, such as MiNK-413 (IL-15 armored CAR-iNKT), and a proprietary personalized neoantigen library for TCR-based therapies [sec_mda · as of 2026-03-31].
What works
- agenT-797 has entered randomized Phase 2 clinical validation in ARDS, a high-impact indication with a clear path to data readout [news · 2026-05-15].
- Non-dilutive funding from NIH and other grants supports the GVHD program, reducing near-term cash burn [sec_mda · as of 2026-08-13].
- The company has a diversified pipeline including both native and engineered iNKT assets, as well as a personalized neoantigen library platform [sec_mda · as of 2026-03-31].
What to weigh
- Cash & equivalents of $8.8M as of 2026-06-30 are limited relative to ongoing clinical and operational expenses [sec].
- The company has an accumulated deficit of $162.5 million and has incurred annual operating losses since inception in 2017 [sec_mda · as of 2026-08-13].
- Shareholders' equity is negative at -$14.0M as of 2026-06-30, indicating liabilities exceed assets [sec].
- The ARDS program faces a competitive landscape with at least 98 competitors, including other Phase 2 and Phase 3 agents [pipeline].
From the filings
Quoted directly from source documents.
Accumulated deficit
“we had an accumulated deficit of $162.5 million as of”
SEC MD&A · August 13, 2026
Phase 2 trial initiation and data timing
“Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026”
News · May 15, 2026
Non-dilutive funding for GVHD program
“The program is supported by non-dilutive funding, including an NIH STTR grant from the National Institute of Allergy and Infectious Diseases (NIAID) for preclinical development and the Mary Gooze Clinical Trial Award to the University of Wisconsin-Madison”
SEC MD&A · August 13, 2026
Catalyst timeline
- 2026-05-26 · Phase 2 Adaptive Randomized, Placebo-Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria — Initiation of the randomized Phase 2 trial for agenT-797 in ARDS; preliminary data expected in H2 2026.
Risks & what to watch (4)›
Key risks
- Limited cash runway — Cash & equivalents of $8.8M as of 2026-06-30 may constrain operations if no additional funding or revenue materializes [sec].
- Negative shareholders' equity — Shareholders' equity of -$14.0M as of 2026-06-30 indicates the company is technically insolvent on a balance sheet basis [sec].
- Competitive ARDS landscape — The ARDS program competes with 98 other agents, including multiple Phase 2 and Phase 3 candidates [pipeline].
- No approved products — MiNK has no approved products and relies on future clinical and regulatory success for revenue [sec_mda · as of 2026-03-31].
What to watch
- Preliminary data from the Phase 2 ARDS trial of agenT-797 expected in the second half of 2026 [news · 2026-05-15].
- First patient dosing in the investigator-sponsored Phase 1 GVHD trial expected in mid-2026 [sec_mda · as of 2026-08-13].
- Cash burn rate and any new financing or partnership announcements given the $8.8M cash position [sec].
- Progress of next-generation engineered iNKT programs (e.g., MiNK-413) toward clinical entry [sec_mda · as of 2026-08-13].
Sources: Catalysts · News · Pipeline · SEC filings · SEC MD&A · Generated October 12, 2026 · How we verify sources →
Run MiNK Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available MiNK Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
Net income -$3M
Lead: Phase 2
1 candidate
No upcoming catalysts tracked
0 buys · 2 sells (180d)
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
22
Total value held
$1.3M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 59,364 | $625K |
| geode capital management, llc | 17,345 | $183K |
| longbow finance sa | 16,667 | $176K |
| ubs group ag | 15,202 | $160K |
| vanguard fiduciary trust co | 8,287 | $87K |
| blackrock, inc. | 6,203 | $65K |
| steward partners investment advisory, llc | 2,000 | $21K |
| annis gardner whiting capital advisors, llc | 200 | $2K |
| tower research capital llc (trc) | 156 | $2K |
| morgan stanley | 104 | $1K |
Showing top 10 of 22 institutional holders of MiNK Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of May 21, 2026- % of float
- 4.0%
- Days to cover
- 1.7
- Shares short
- 97,106
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
INKT short interestGovernance
Frequently asked questions
What is the AI investment thesis for MiNK Therapeutics, Inc.?
MiNK Therapeutics, Inc. (INKT) is a publicly traded biotechnology company developing allogeneic invariant natural killer T (iNKT) cell therapies for cancer, acute respiratory distress syndrome (ARDS), and graft-versus-host disease (GVHD), with its lead candidate agenT-797 in Phase 2 clinical trials.
What is MiNK Therapeutics, Inc.'s lead drug candidate?
MiNK Therapeutics, Inc.'s most advanced tracked candidate is agent-797 (Phase 2) for Respiratory Distress Syndrome, Adult; Pneumonia.
Who is the CEO of MiNK Therapeutics, Inc.?
Dr. Jennifer S. Buell Ph.D. is the chief executive officer of MiNK Therapeutics, Inc. (INKT).
Where is MiNK Therapeutics, Inc. headquartered?
MiNK Therapeutics, Inc. (INKT) is headquartered in New York, NY, United States.
What therapeutic areas does MiNK Therapeutics, Inc. focus on?
MiNK Therapeutics, Inc. develops therapies across Infectious Disease, Respiratory.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.